Introduction
While variant histology within urothelial bladder cancer has been documented for decades, the World Health Organization (WHO) did not include variant histology in bladder cancer classifications until 2004, and the clinical significance of variant bladder
cancer has yet to be fully determined 1, 2 . Collectively, variant histology is often associated with more advanced disease and worse survival [3] [4] [5] [6] . Nonetheless, the heterogeneity of urothelial bladder cancer and the ability to display clinicopathologic characteristics of single or multiple variant subtypes has complicated the understanding of variant tumor biology even further.
As one of the first classified variants, squamous differentiation (SQD) has consistently been described as the most common variant subtype, comprising anywhere between 30-80% of variant bladder cancers 2, 3, [6] [7] [8] [9] [10] . Although SQD was previously shown to be associated with higher pathologic staging and increased risk of local recurrence, when accounting for stage, SQD does not alter overall survival (OS) or disease-specific survival (DSS) 7, 8, [11] [12] [13] . Furthermore, there is evidence suggesting that SQD may be equally sensitive to chemotherapy as non-variant (NV) urothelial bladder cancer 10, 12, [14] [15] [16] [17] .
Although SQD and NV seem to act similarly, many of the previous studies on SQD derive from older cohorts of patients, prior to the 2004 WHO classifications 1 . Since use of systemic chemotherapy has increased, peri-operative care and surgical techniques have improved, and awareness of less commonly described variants has increased, we sought to assess whether SQD confers worse prognosis than NV urothelial cancer in a contemporary series of patients undergoing radical cystectomy.
Materials and Methods

Population
Institutional Review Board approval was granted for the conduct of this study.
We conducted a retrospective cohort analysis of our Institutional Bladder Cancer Database to identify all patients with urothelial carcinoma undergoing radical cystectomy with curative intent between 2003 and 2013 (n=934). Patients with non-urothelial cancer on transurethral resection of bladder tumor (TURBT) or cystectomy pathology were not included in this cohort. As the primary focus of this project was comparison of SQD with NV patients, patients with other variant histology on either TURBT or cystectomy (n=199) were excluded. SQD variant status was assigned by central pathologic review.
A single dedicated genito-urinary pathologist reviewed all cases. All outside TURBT specimens were also re-reviewed by the genito-urinary pathologist. In the setting of unclear pathology, slides were reviewed with other dedicated genito-urinary pathologists in the department to determine appropriate assignment of variant status. Any component of SQD variant histology with primary urothelial bladder cancer was considered sufficient to be identified as SQD for the purposes of this study.
Outcomes and variables
The primary outcomes of interest in this study were non-organ confined disease at the time of radical cystectomy, disease specific survival (DSS), and overall survival (OS). These were thought to represent both short and long term oncologic outcomes.
Non-organ confined disease was defined as ≥pT3 or lymph node (LN) involvement. OS and DSS were assessed using our Institutional Cancer Registry and electronic medical records.
Variables included in the analyses were demographic, TURBT related, cystectomy related, and therapy related. Demographic variables were age, sex, and 
Statistical analyses
Descriptive analysis was performed using Pearson's chi-squared test, Student's t-test, Fishers exact test, and the Mann-Whitney U-test as appropriate to the data. In the setting of non-normally distributed data, the median with interquartile range (IQR) are presented. Kaplan-Meier methodology with log-rank test was used to evaluate DSS and OS for SQD and NV patients. Cox proportional hazards regression models were generated to evaluate the relationship between SQD and both disease specific and allcause mortality. These models were adjusted for age, sex, systemic chemotherapy, pathologic stage, and LN status. Variables chosen for inclusion in the models were decided upon a priori as variables considered to have the potential to confound the relationship between SQD variant histology and survival. A priori significance was set at p<0.05 for two-tailed tests. All statistical analyses were performed using Stata 12.1 (Stata Corp. LP, College Station, TX).
Results
Among the patients who underwent radical cystectomy, 735 patients met inclusion criteria. Six hundred and seventeen (83.9%) tumors displayed NV histology while the remaining 118 patients had SQD (16.1%). Twenty-six patients had SQD identified exclusively on TURBT, forty-two had SQD exclusively on cystectomy, and forty-three had SQD identified on both TURBT and cystectomy specimens. SQD patients made up 37% (118/317) of variant bladder cancer patients. SQD patients were older than NV patients (68.5 vs 66.1 years, p=0.033) and a greater proportion were female (31% vs 20%, p=0.009). On TURBT a higher proportion of SQD patients had evidence of muscle invasion (75% vs 59%, p=0.002) although incidence of LVI and CIS were similar between cohorts (Table 1) .
SQD patients had higher pathologic staging (p=0.001). Although SQD patients had higher incidence of non-organ confined disease (57% vs 44%, p=0.009), there was no significant difference in the proportion of patients with positive surgical margins or positive LN (Table 2) . A higher proportion of NV patients were identified as having CIS on cystectomy pathology (57% vs 44%, p=0.038). NV and SQD patients received systemic chemotherapy comparably (23% vs 24%, p=0.836) ( Table 2 ).
Median follow-up for the cohort was 52 (range: 30-83) months. Although SQD and NV patients had similar OS, SQD patients had worse DSS (p=0.049) (Figure 1a,b) . SQD and NV patients had similar OS and DSS when compared based on organconfined disease at time of cystectomy or muscle invasion at TURBT (Figure 2a Table 3) . Increasing pathologic stage and positive lymph nodes were the only factors associated with increased risk of disease-specific and all-cause mortality (Table 3) .
Discussion
Understanding the clinical significance of variant histology, when combined with other clincopathologic factors, may improve the ability to individualize treatment and counseling of patients. While recent studies have found certain variants such as micropapillary and plasmacytoid to act more aggressively, SQD has been historically described to act similarly to NV histology 5, 11, 14, 15, 18, 19 . However, much of the SQD literature draws on older cohorts. These reports may have missed less common variants such as micropapillary, plasmacytoid, and sacromatioid and grouped these patients . Therefore, we provide an analysis of our experience with SQD and NV urothelial carcinoma among a well-defined, contemporary cohort of patients, whose variant histology has been assigned through a centralized pathologic review process.
While much has been published on SQD, the true prevalence of SQD tumors is unknown. As the earliest documented variant, older cohorts found SQD tumors to comprise upwards of 80% of variant bladder cancers 2, 21, 22 . However more recent studies have demonstrated SQD to make up a lower proportion of variant bladder cancers 6, 7 . Our cohort of patients demonstrated that the proportion of variant bladder . Wasco et al found the difference in muscle invasive disease on TURBT to be less dramatic but still significant in a cohort of radical cystectomy patients 6 . They reported 85.7% of SQD patients and 52.3% of NV patients having muscle invasive disease. Our study is consistent with the prior reports with 75% of SQD and 59% of NV patients having muscle invasion. While the difference in muscle invasion between SQD and NV tumors is more drastic when looking at all TURBT specimens, even in cohorts of only radical cystectomy patients, SQD tumors demonstrates muscle invasion more often.
Consistent with the TURBT findings, SQD have historically been known to have more advanced pathologic disease 7, 8, 23 . Kim et al found that variant tumors had almost double the incidence of non-organ confined disease as well as increased LN involvement 7 . These findings were corroborated by Xylinas et al that also demonstrated more advanced pathologic staging and LN involvement in SQD patients 23 . We too demonstrate more advanced pathologic staging in our SQD patients, but we found no significant difference in LN status at the time of radical cystectomy.
While there is relatively limited literature addressing chemotherapy response in variant bladder cancer, SQD has been previously shown to be equally chemosensitive as NV urothelial carcinoma 12, [14] [15] [16] . Logothetis et al published two retrospective studies using CISCA (cisplatin, cyclophosphamide, and doxorubicin) for adjuvant treatment or salvage therapy in SQD patients. Both studies reported SQD to have similar responses to chemotherapy compared to the NV group. Similarly, Kastritis et al found that when treating advanced or metastatic urothelial carcinoma with a platinum-based chemotherapy regimen, SQD and NV bladder cancer exhibited similar responsiveness 16 . Lastly, in a secondary analysis of the SWOG S8710 clinical trial using neoadjuvant MVAC (methotrexate, vincristine, doxorubicin, and cisplatin), SQD demonstrated nonstatistically significant (p=0.09) improved survival benefit compared to NV in locally advanced urothelial carcinoma 14 . In our cohort, patients receiving neoadjuvant chemotherapy responded at similar rates although we are significantly underpowered to fully evaluate this. Although systemic chemotherapy was not associated with OS or DSS on multivariate analysis, we likely are underpowered to determine a difference.
When comparing unadjusted DSS in SQD and NV patients, SQD patients did worse. However, after grouping patients based on muscle invasion on TURBT, the difference no longer exists. This finding remains consistent when comparing based on organ and non-organ confined disease on post-cystectomy pathology. Furthermore, on Cox proportional hazards regression, only pathologic staging and LN status were associated with increased risk of disease specific and all-cause mortality. Our findings are consistent with previously reported studies that have shown that SQD does not portend worse survival on multivariate analysis 6, 7, 11, 23 .
There are limitations to our study that warrant discussion. Our study is a retrospective review of urothelial carcinoma patients operated on by multiple surgeons at a single, high volume tertiary center. Therefore, both the surgical technique as well as the patient population may not be generalizable to all practices. A recent report demonstrated that extent of SQD was associated with worse survival by univariate analysis, but lost significance under multivariate analysis. 24 Unfortunately, we are unable to evaluate the impact that extent of SQD has on clinicopathologic outcomes, which is an important next step in research on variant histology. Finally, as only a small proportion of patients underwent neoadjuvant chemotherapy, it is inappropriate to draw conclusions regarding response to chemotherapy from our cohort of patients.
Nevertheless, given these limitations, we believe our analysis bolsters the understanding of SQD in relation to NV urothelial carcinoma. Despite more advanced disease at presentation and final pathology, DS and all-cause mortality may be similar between SQD and NV.
Conclusions
We found that SQD represents a smaller proportion of variant urothelial bladder cancers than what had previously been reported likely as a result of increased awareness towards non-SQD histology within urothelial bladder cancer. Although SQD patients present at an advanced stage, the histologic variant itself does not signify worse survival. These findings may have important implications on the management and counseling of SQD patients after TURBT and cystectomy. Further understanding SQD response to radiation and chemotherapy should be an important consideration for future studies, but there is significant evidence to suggest SQD is equally chemosensitive.
Given our current knowledge of SQD histology, counseling and treating SQD patients similar to NV patients would seem appropriate. NV organ confined vs. SQD organ confined, p=0.2528 NV non-organ confined vs. SQD non-organ confined, p=0.0732
